Pathogenesis and Implications for Neuroprotection
The role of parkin in familial and sporadic Parkinson's disease†
Ted M. Dawson MD, PhD,
Valina L. Dawson PhD,
Corresponding Author
Ted M. Dawson MD, PhD
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, 733 North Broadway, BRB 731, Baltimore, MD 21205Search for more papers by this authorValina L. Dawson PhD
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorTed M. Dawson MD, PhD,
Valina L. Dawson PhD,
Corresponding Author
Ted M. Dawson MD, PhD
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, 733 North Broadway, BRB 731, Baltimore, MD 21205Search for more papers by this authorValina L. Dawson PhD
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this author†
Potential conflict of interest: Nothing to report.
Abstract
Mutations in parkin are the second most common known cause of Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that monoubiquitinates and polyubiquitinates proteins to regulate a variety of cellular processes. Loss of parkin's E3 ligase activity is thought to play a pathogenic role in both inherited and sporadic PD. Here, we review parkin biology and pathobiology and its role in the pathogenesis of PD. © 2010 Movement Disorder Society
REFERENCES
- 1 Gasser T. Genetics of Parkinson's disease. J Neurol 2001; 248: 833–840.
- 2 Dawson TM. New animal models for Parkinson's disease. Cell 2000; 101: 115–118.
- 3 Dawson TM,Dawson VL. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 2003; 111: 145–151.
- 4 Giasson BI,Lee VM. Parkin and the molecular pathways of Parkinson's disease. Neuron 2001; 31: 885–888.
- 5 Lansbury PT,Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 2002; 12: 299–306.
- 6 Lim KL,Dawson VL,Dawson TM. The genetics of Parkinson's disease. Curr Neurol Neurosci Rep 2002; 2: 439–446.
- 7 Savitt JM,Dawson VL,Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744–1754.
- 8 Polymeropoulos MH,Higgins JJ,Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996; 274: 1197–1199.
- 9 Polymeropoulos MH,Lavedan C,Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]. Science 1997; 276: 2045–2047.
- 10 Kitada T,Asakawa S,Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605–608.
- 11 Bonifati V,Rizzu P,Van Baren MJ, et al. Mutations in the DJ-1gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256–259.
- 12 Valente EM,Abou-Sleiman PM,Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158–1160.
- 13 Paisan-Ruiz C,Jain S,Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595–600.
- 14 Zimprich A,Biskup S,Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601–607.
- 15 Deshaies RJ,Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399–434.
- 16 Klein C,Lohmann K. Parkinson disease(s): is “parkin disease” a distinct clinical entity? Neurology 2009; 72: 106–107.
- 17 Klein C,Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007; 69: 2093–2104.
- 18 Pilcher H. Parkin implicated in sporadic Parkinson's disease. Lancet Neurol 2005; 4: 798.
- 19 Ishikawa A,Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol 1998; 245:(11 Suppl 3 ) P4–P9.
- 20 Farrer M,Chan P,Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001; 50: 293–300.
- 21 Pramstaller PP,Schlossmacher MG,Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 parkin mutation carriers. Ann Neurol 2005; 58: 411–422.
- 22 Sasaki S,Shirata A,Yamane K,Iwata M. Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology 2004; 63: 678–682.
- 23 Mori H,Kondo T,Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998; 51: 890–892.
- 24 Van De Warrenburg BP,Lammens M,Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001; 56: 555–557.
- 25 Shimura H,Hattori N,Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302–305.
- 26 Zhang Y,Gao J,Chung KK,Huang H,Dawson VL,Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000; 97: 13354–13359.
- 27 Imai Y,Soda M,Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000; 275: 35661–35664.
- 28 Hershko A,Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425–479.
- 29 Fallon L,Belanger CM,Corera AT, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 2006; 8: 834–842.
- 30 Lim KL,Chew KC,Tan JM, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005; 25: 2002–2009.
- 31 Lim KL,Dawson VL,Dawson TM. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiol Aging 2006; 27: 524–529.
- 32 Imai Y,Soda M,Inoue H,Hattori N,Mizuno Y,Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001; 105: 891–902.
- 33 Doss-Pepe EW,Chen L,Madura K. Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J Biol Chem 2005; 280: 16619–16624.
- 34 Hampe C,Ardila-Osorio H,Fournier M,Brice A,Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 2006; 15: 2059–2075.
- 35 Matsuda N,Kitami T,Suzuki T,Mizuno Y,Hattori N,Tanaka K. Diverse effects of pathogenic mutations of parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 2006; 281: 3204–3209.
- 36 West AB,Maidment NT. Genetics of parkin-linked disease. Hum Genet 2004; 114: 327–336.
- 37 West AB,Moore DJ,Choi C, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007; 16: 223–232.
- 38 West AB,Dawson VL,Dawson TM. The role of parkin in Parkinson's disease. In: TM Dawson, editor. Parkinson's disease: genetics and pathogenesis. New York: Informa Healthcare USA, Inc.; 2007. p 199–218.
- 39 Wang C,Tan JM,Ho MW, et al. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J Neurochem 2005; 93: 422–431.
- 40 Winklhofer KF,Henn IH,Kay-Jackson PC,Heller U,Tatzelt J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem 2003; 278: 47199–47208.
- 41 Chung KK,Thomas B,Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004; 304: 1328–1331.
- 42 Yao D,Gu Z,Nakamura T, et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 2004; 101: 10810–10814.
- 43 Lavoie MJ,Ostaszewski BL,Weihofen A,Schlossmacher MG,Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 1214–1221.
- 44 Wang C,Ko HS,Thomas B, et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 2005; 14: 3885–3897.
- 45 Wong ES,Tan JM,Wang C, et al. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J Biol Chem 2007; 282: 12310–12318.
- 46 Dong Z,Ferger B,Paterna JC, et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc Natl Acad Sci U S A 2003; 100: 12438–12443.
- 47 Periquet M,Corti O,Jacquier S,Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 2005; 95: 1259–1276.
- 48 Yang Y,Nishimura I,Imai Y,Takahashi R,Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003; 37: 911–924.
- 49 Chung KK,Zhang Y,Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7: 1144–1150.
- 50 Tan JM,Wong ES,Dawson VL,Dawson TM,Lim KL. Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. Autophagy 2008; 4: 251–253.
- 51 Tan JM,Wong ES,Kirkpatrick DS, et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 2008; 17: 431–439.
- 52 Olzmann JA,Li L,Chudaev MV, et al. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 2007; 178: 1025–1038.
- 53 Corti O,Hampe C,Koutnikova H, et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 2003; 12: 1427–1437.
- 54 Ko HS,Von Coelln R,Sriram SR, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 2005; 25: 7968–7978.
- 55 Ko HS,Kim SW,Sriram SR,Dawson VL,Dawson TM. Identification of far upstream element-binding protein-1 as an authentic parkin substrate. J Biol Chem 2006; 281: 16193–16196.
- 56 Yang F,Jiang Q,Zhao J,Ren Y,Sutton MD,Feng J. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 2005; 280: 17154–17162.
- 57 Huynh DP,Scoles DR,Nguyen D,Pulst SM. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet 2003; 12: 2587–2597.
- 58 Choi P,Snyder H,Petrucelli L, et al. SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res 2003; 117: 179–189.
- 59 Staropoli JF,Mcdermott C,Martinat C,Schulman B,Demireva E,Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003; 37: 735–749.
- 60 Um JW,Min DS,Rhim H,Kim J,Paik SR,Chung KC. Parkin ubiquitinates and promotes the degradation of RanBP2. J Biol Chem 2006; 281: 3595–3603.
- 61 Moore DJ,West AB,Dikeman DA,Dawson VL,Dawson TM. Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem 2008; 105: 1806–1819.
- 62 Joch M,Ase AR,Chen CX, et al. Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol Biol Cell 2007; 18: 3105–3118.
- 63 Lim MK,Kawamura T,Ohsawa Y, et al. Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination. Exp Cell Res 2007; 313: 2858–2874.
- 64 Huynh DP,Nguyen DT,Pulst-Korenberg JB,Brice A,Pulst SM. Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp Neurol 2007; 203: 531–541.
- 65 Darios F,Corti O,Lucking CB, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 2003; 12: 517–526.
- 66 Higashi Y,Asanuma M,Miyazaki I,Hattori N,Mizuno Y,Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. J Neurochem 2004; 89: 1490–1497.
- 67 Jiang H,Ren Y,Zhao J,Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 2004; 13: 1745–1754.
- 68 Perez FA,Curtis WR,Palmiter RD. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci 2005; 6: 71.
- 69 Thomas B,Von Coelln R,Mandir AS, et al. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 2007; 26: 312–322.
- 70 Petrucelli L,O'farrell C,Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007–1019.
- 71 Yamada M,Mizuno Y,Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 2005; 16: 262–270.
- 72 Liani E,Eyal A,Avraham E, et al. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101: 5500–5505.
- 73 Von Coelln R,Thomas B,Andrabi SA, et al. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J Neurosci 2006; 26: 3685–3696.
- 74 Palacino JJ,Sagi D,Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in Parkin-deficient mice. J Biol Chem 2004; 279: 18614–18622.
- 75 Greene JC,Whitworth AJ,Kuo I,Andrews LA,Feany MB,Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 2003; 100: 4078–4083.
- 76 Pesah Y,Pham T,Burgess H, et al. drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004; 131: 2183–2194.
- 77 Muftuoglu M,Elibol B,Dalmizrak O; et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004; 19: 544–548.
- 78 Kuroda Y,Mitsui T,Kunishige M, et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 2006; 15: 883–895.
- 79 Pawlyk AC,Giasson BI,Sampathu DM, et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 2003; 278: 48120–48128.
- 80 Park J,Lee SB,Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157–1161.
- 81 Clark IE,Dodson MW,Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162–1166.
- 82 Tan JM,Dawson TM. Parkin blushed by PINK1. Neuron 2006; 50: 527–529.
- 83 Exner N,Treske B,Paquet D, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007; 27: 12413–12418.
- 84 Poole AC,Thomas RE,Andrews LA,Mcbride HM,Whitworth AJ,Pallanck LJ. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 2008; 105: 638–1643.
